NewAmsterdam Pharma N.V. (NAMS) vs Zai Lab (ZLAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zai Lab (ZLAB) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, losing 23.6% versus a loss of 34.6%. Over five years, NAMS leads with a +120.4% price change compared with -75.5% for ZLAB. Zai Lab is the larger company by market cap ($2.81 billion vs $2.52 billion), about 1.1 times the size.
Zai Lab converts more of its revenue into profit, with a net margin of -38.1% versus -905.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAMS | ZLAB |
|---|---|---|
| Share price | $21.58 | $24.99 |
| Market cap | $2.52B | $2.81B |
| 1-day change | +1.48% | +0.73% |
| YTD return | -38.50% | +41.67% |
| 1-year return | -34.63% | -23.58% |
| 5-year return | +120.38% | -75.50% |
| EPS (TTM) | $-2.16 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $22.50M | $460.16M |
| Revenue growth (YoY) | -50.61% | +15.33% |
| Net income (latest FY) | $-203.82M | $-175.54M |
| Gross margin | — | 58.60% |
| Operating margin | -1002.90% | -49.86% |
| Net margin | -905.74% | -38.15% |
| 52-week high | $42.21 | $32.76 |
| 52-week low | $20.91 | $15.96 |
| Distance from 52-week high | -48.88% | -23.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +130.13% | +32.61% |
| Average volume | 1.37M | 945.51K |
| Shares outstanding | 116.90M | 112.27M |
| Employees | 100 | 1,784 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZLAB has outperformed NAMS by 11.1 percentage points over the past year.
- Zai Lab is more profitable, keeping -38.1 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
- Zai Lab grew revenue faster in its latest fiscal year (+15.33% vs -50.61%).
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Zai Lab
ZLAB stock →Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees
NAMS vs ZLAB FAQ
Which is bigger, NewAmsterdam Pharma N.V. or Zai Lab?
Zai Lab (ZLAB) is larger, with a market capitalization of $2.81B compared with $2.52B for NewAmsterdam Pharma N.V. (NAMS).
Which stock has performed better over the past year, NAMS or ZLAB?
ZLAB returned -23.58% over the past 12 months, compared with -34.63% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are NewAmsterdam Pharma N.V. and Zai Lab in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.